Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.

Sunil TanejaAjay DusejaArka DeVivek KumarRaja RamachandranAshish SharmaRadha K DhimanKrishan L GuptaYogesh Chawla

Published in: Nephrology (Carlton, Vic.) (2018)

DAAs including Sofosbuvir, Daclatasvir and Ledipasvir with or without ribavirin are safe and effective for the treatment of chronic hepatitis C in renal transplant recipients.

Keyphrases

hepatitis c virus
combination therapy
liver fibrosis
hepatitis c virus infection